Skip to main content

SureSelect Human All Exon V7

Sleek Design, Best-in-Class Coverage, Minimal Sequencing

SureSelect Human All Exon V7 Hero Image

SureSelect Human All Exon V7

Agilent's latest exome, the SureSelect Human All Exon v7, is a comprehensive exome that focuses on interpretable part of the genome, and also provides a cost-effective hybrid-capture solution. Powered by the unrivaled SureSelect technology, this exome differs from all the other exomes available on the market by its unequaled performance and robustness.

Key Features and benefits

Lower sample sequencing cost

The new and innovative bait design provides superb coverage with minimal sequencing

Access comprehensive content including hard-to-capture exons

This exome was designed with using the most up-to-date versions of RefSeq, GENCODE, CCDS & UCSC Known Genes

Optimized workflow for sample to data

Library prep solution for a seamless optimized workflow for every need, including low input and FFPE samples.

Best-in-class coverage with minimal sequencing

Get the best value for your sequencing dollar

With a sleek design and low sequencing requirements, SureSelect Human All Exon V7 is one of the most cost-effective exome solutions. An innovative bait design approach maximizes coverage with minimal sequencing

Best-in-class coverage with minimal sequencing

The most comprehensive variant detection platform

Access content that matters

SureSelect Human All Exon V7 targets protein coding regions from RefSeq, GENCODE, CCDS, and UCSC Known Genes. Additionally, SureSelect V7 exome targets all pathogenic variants in the genes included in the ACMG guidelines for secondary findings.

SureSelect HumanAll Exon V7 Comprehensive Graph

Seamless exome workflow solution for every need

Experience a seamless workflow

SureSelect Human All Exon V7 is compatible with SureSelect Library Prep solutions making it the one of the most versatile exome solutions. Raw data can be easily uploaded and analyzed using the Agilent Alissa Clinical Informatics Software.